Healthy Adults
Conditions
Interventions
Ingest 1,050 mL of the test food (black tea) once a day, daily for 8 weeks.
Sponsors
Healthcare Systems Co., Ltd.
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1) Persons who received a sufficient explanation of the purpose and contents of the study, have the capacity to consent, applied with free will with sufficient understanding, and agreed to participate. 2) Japanese females who are 30 years old or more and under 50 years old at the time of informed consent. 3) Persons who have concerns about their skin.
Exclusion criteria
Exclusion criteria: 1) Persons who have chronic illness, receiving medication, or have a serious disease history. 2) Persons who are allergic to the test food. 3) Persons who usually take a large amount of black tea (3 cups or more per day). 4) Persons who usually take medicine, health foods (specified health foods, functional foods, and functional nutrition foods), or other supplements expected to have cosmetic effects. 5) Persons who have experienced cosmetic medicine on the face. 6) Persons who have inflammation or skin disease on the face. 7) Persons receiving hormone replacement therapy. 8) Persons with eyelash extensions. 9) Persons with permanent makeup on the corners of the eyes. 10) Persons whose measurement date may overlap with their menstrual period. 11) Persons who may develop seasonal allergic symptoms such as hay fever and may use medications during the study period. 12) Persons who have participated in other studies within one month before the start of the study, or who plan to participate in another study after consenting to this study. 13) Persons who were judged as inappropriate for study participants by the principal investigator or the research director. 14) Persons who are pregnant, planning or hoping to be pregnant during the study period, or breastfeeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Skin examination (stratum corneum hydration, transepidermal water loss, skin viscoelasticity, and VISIA image analysis) at baseline, 4 weeks, and 8 weeks after the start of intake. | — |
Secondary
| Measure | Time frame |
|---|---|
| Urinary 8-OHdG, and VAS questionnaire (skin condition, physical condition, and bowel movements) at baseline, 4 weeks, and 8 weeks after the start of intake. | — |
Countries
Japan
Contacts
Public ContactTakamasa Masuda
Healthcare Systems Co., Ltd. Clinical Research Department
Outcome results
None listed